Search

Your search keyword '"Delmas Y."' showing total 246 results
Start Over Author "Delmas Y."
246 results on '"Delmas Y."'

2. Cardiac troponin‐I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center

Author

Benhamou, Y., Boelle, P.‐Y., Baudin, B., Ederhy, S., Gras, J., Galicier, L., Azoulay, E., Provôt, F., Maury, E., Pène, F., Mira, J.‐P., Wynckel, A., Presne, C., Poullin, P., Halimi, J.‐M., Delmas, Y., Kanouni, T., Seguin, A., Mousson, C., Servais, A., Bordessoule, D., Perez, P., Hamidou, M., Cohen, A., Veyradier, A., Coppo, P., Elie, Azoulay, Virginie, Barbay, Guy, Bonmarchand, Dominique, Bordessoule, Christophe, Charasse, Dominique, Chauveau, Gabriel, Choukroun, Jean‐Philippe, Coindre, Paul, Coppo, Elise, Corre, Yahsou, Delmas, Georges, Deschenes, Alain, Devidas, Olivier, Fain, Véronique, Frémeaux‐Bacchi, Lionel, Galicier, Bertrand, Guidet, Jean‐Michel, Halimi, Mohamed, Hamidou, Raoul, Herbrecht, Frédéric, Jacobs, Bérangère, Joly, Tarik, Kanouni, Alexandre, Lautrette, Véronique, Le Guern, Chantal, Loirat, Jean‐Paul, Mira, Bruno, Moulin, Christiane, Mousson, Mario, Ojeda Uribe, Abdelkader, Ouchenir, Nathalie, Parquet, Julie, Peltier, Pierre, Perez, Pascale, Poullin, Claire, Pouteil‐Noble, Claire, Presne, François, Provôt, Jean‐Antoine, Ribeil, Eric, Rondeau, Samir, Saheb, Benoît, Schlemmer, Amélie, Seguin, Alain, Stépanian, Jean‐Paul, Vernant, Agnès, Veyradier, Cécile, Vigneau, François, Vrtovsnick, Alain, Wynckel, Martine, Wolf, and Patricia, Zunic

Published
2015
Full Text
View/download PDF

3. Les syndromes hémolytiques et urémiques de l’adulte associés aux infections à Escherichia coli producteur de Shigatoxine en France de 2009 à 2017

Author

Travert, B., primary, Dossier, A., additional, Cointe, A., additional, Delmas, Y., additional, Bouadma, L., additional, Hie, M., additional, Galicier, L., additional, Hertig, A., additional, Hogan, J., additional, Daugas, E., additional, Benhamou, Y., additional, Fremeaux-Bacchi, V., additional, Mariani-Kurkdjian, P., additional, Rondeau, E., additional, and Coppo, P., additional

Published
2021
Full Text
View/download PDF

7. [Recommendations for management of patients from pediatrics unit to adult unit: Transition and transfer program]

Author

Lemoine, S., Radenac, J., Baudouin, V., Belaiche, S., Bertholet-Thomas, A., Buebuyck, N., Broux, F., Burtey, S., Champion, G., Charbit, M., Cochat, P., De Parscau, L., Delmas, Y., DUNAND, O., Essig, M., Guebre-Egziabher, F., Langellier-Bellevue, B., Leclerc, A. L., Merieau, É, Moulin, B., Perrin, J., Rousiot, D., Sartoris, B., SERVAIS, A., Nagra, A., Novo, R., Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Université de Lyon, Centre de référence des maladies rénales rares Néphrogones [CHU-HCL, Lyon], Hôpital Femme Mère Enfant [CHU - HCL] (HFME), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Hôpital Robert Debré, CHU Lille, CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Référence des Maladies Rénales Héréditaires de l'Enfant et de l'Adulte (MARHEA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Charles Nicolle [Rouen], Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), CHU Bordeaux [Bordeaux], Centre De Référence des Maladies Rénales Rares du Sud Ouest (SORARE), Centre De Référence des Maladies Rénales Rares du Sud Ouest, Centre hospitalier Félix-Guyon [Saint-Denis, La Réunion], Hôpital Ambroise Paré [AP-HP], Hôpital Gatien de Clocheville [Tours] (CHRU Tours), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Nouvel Hôpital Civil de Strasbourg, Università degli studi di Trieste, INAF - Osservatorio Astronomico di Trieste (OAT), Istituto Nazionale di Astrofisica (INAF), Département de Néphrologie [CHU Necker], Hôpital Jeanne de Flandres, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre de Référence des Maladies Rénales Héréditaires de l'Enfant et de l'Adulte [CHU-Necker] (MARHEA), CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Università degli studi di Trieste = University of Trieste, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], and CarMeN, laboratoire

Subjects
[SDV] Life Sciences [q-bio], Non adhérence, Transfert, [SDV]Life Sciences [q-bio], Transition, Empowerment, ComputingMilieux_MISCELLANEOUS
Abstract

International audience; No abstract available

Published
2021

8. Outcome of children with Shiga toxin-associated haemolytic uraemic syndrome treated with eculizumab: a matched cohort study

Author

MONET-DIDAILLER, C., Chevallier, A., GODRON-DUBRASQUET, A., Allard, L., Delmas, Y., Contin-Bordes, C., Brissaud, O., Llanas, B., HARAMBAT, Jerome, Bordeaux population health (BPH), and Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, urologic and male genital diseases
Abstract

BACKGROUND: Treatment with eculizumab in Shiga toxin-associated haemolytic and uraemic syndrome (STEC-HUS) remains controversial despite its increasing utilization. The aim of our study was to evaluate the outcomes of children treated with eculizumab for STEC-HUS in a single-centre matched cohort study. METHODS: Data were retrospectively collected from medical records of children diagnosed with STEC-HUS. The outcomes of patients treated with eculizumab for STEC-HUS were compared with those of a control group of untreated patients matched for age, sex and severity of acute kidney injury with a 1:2 matching scheme. RESULTS: Eighteen children (median age 40.6 months) with STEC-HUS treated with eculizumab were compared with 36 matched control patients (median age 36.4 months) who did not receive eculizumab. All patients survived in the two groups. Within 1 month of HUS onset, the evolution of haematological and renal parameters did not differ between the two groups. At 12 months of follow-up, renal outcome was not significantly different between the two groups. At the last follow-up, the prevalence of decreased glomerular filtration rate in the eculizumab group (27%) was not statistically different from that in controls (38%), as was the prevalence of proteinuria and high blood pressure. Children who received eculizumab more often had extrarenal sequelae during follow-up. Eculizumab treatment appeared to be safe in children with STEC-HUS. CONCLUSION: The benefit of eculizumab on renal and extrarenal outcomes in STEC-HUS could not be established based on our findings. However, efficacy and safety are not best assessed by the observational design and small sample size of our study. Randomized controlled trials are thus required to determine the efficacy of eculizumab in this indication.

Published
2020

10. Experimental investigation on the mechanical performance of starch-hemp composite materials

Author

Le, A.T., Gacoin, A., Li, A., Mai, T.H., Rebay, M., and Delmas, Y.

Subjects
Binders (Materials) -- Usage, Composite materials -- Mechanical properties, Business, Construction and materials industries
Abstract

ABSTRACT An experimental investigation was conducted in order to study the mechanical performance of starchhemp composite materials. The starch-hemp composite material is 100% natural fibers and a durable material. The [...]

Published
2014
Full Text
View/download PDF

13. Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

Author

Legendre, C. M., Licht, C., Muus, P., Greenbaum, L. A., Babu, S., Bedrosian, C., Bingham, C., Cohen, D. J., Delmas, Y., Douglas, K., Eitner, F., Feldkamp, T., Fouque, D., Furman, R. R., Gaber, O., Herthelius, M., Hourmant, M., Karpman, D., Lebranchu, Y., Mariat, C., Menne, J., Moulin, B., Nürnberger, J., Ogawa, M., Remuzzi, G., Richard, T., Sberro-Soussan, R., Severino, B., Sheerin, N. S., Trivelli, A., Zimmerhackl, L. B., Goodship, T., and Loirat, C.

Published
2013
Full Text
View/download PDF

18. Long-term outcome of diarrhea-associated hemolytic uremic syndrome is poorly related to markers of kidney injury at 1-year follow-up in a population-based cohort

Author

MONET-DIDAILLER, C., GODRON-DUBRASQUET, A., MADDEN, I., Delmas, Y., Llanas, B., HARAMBAT, Jerome, Bordeaux population health (BPH), and Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
urogenital system, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, LEHA
Abstract

BACKGROUND: Hemolytic uremic syndrome due to Shiga toxin-producing E. coli (STEC-HUS) is the main cause of acute kidney injury in young children. Most fully recover kidney function; however, some develop long-term sequelae. We aimed to determine whether kidney injury 1 year after HUS onset is associated with long-term kidney outcome in pediatric STEC-HUS. METHODS: A retrospective population-based study of children < 15 years with STEC-HUS between 1992 and 2012 was performed. Mixed effects logistic regression was used to investigate associations between kidney injury at 1 year and long-term kidney outcome. RESULTS: Ninety-eight STEC-HUS cases were reported. Of 96 patients who survived acute phase, 84 were evaluated at 1-year follow-up of whom 42 (44% of survivors) showed >/= 1 signs of kidney injury. Data from 81 patients were collected after median follow-up of 8.7 (IQR 3.5-12.7) years. At last follow-up, 42 (44% of survivors) had >/= 1 signs of kidney injury including decreased estimated glomerular filtration rate (eGFR) < 90 mL/min/1.73 m(2) (n = 30), proteinuria (n = 17), or hypertension (n = 5). Among 42 patients with kidney injuries at 1-year follow-up, only 22 (52%) still had kidney disease at last follow-up. Conversely, of 33 patients without kidney injury at 1-year and available long-term outcome data, 11 (33%) had proteinuria or decreased GFR at last follow-up. There was no statistically significant association between kidney injury at 1 year and long-term kidney outcome. CONCLUSIONS: Since kidney sequelae may appear at variable time intervals after acute HUS, all patients need lifelong follow-up to detect early signs of chronic kidney disease and propose measures to slow progression.

Published
2019

24. Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

Author

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS, Tempo team, Gross P, Schulze B, Bichet D, Chauveau D, Peeters P, Voiculescu M, Manunta P, Tuazon J, Watnick T, Goral S, Horie S, Nutahara K, Torres V, Chapman A, Gansevoort R, Perrone R, Czerwiec F, Goldstein S, Cowley B, Fukagawa M, Torra R, Wei LJ, Cook T, Toto R, Agarwal R, August P, Bakris G, Beddhu S, Corwin H, Ruilope L, Rosa-Diez G, De La Fuente J, Martin R, Massari P, Novoa P, Rial M, Wasserman A, Faull R, Fraser I, Johnson D, Pedagagos E, Lian M, Pollock C, Cooper B, Rangan G, Russ G, McDonald S, Thomas M, Khoo D, Walker R, Pirson Y, Laecke V, Van der Niepen P, Sennesael J, Barre P, Alam A, Soroka S, Dieperink H, Strandgaard S, Petersen L, Berthoux F, Canaud B, Gontiers-Picard A, Huart A, Combe C, Delmas Y, Dussol B, Laville M, Guebre-Egziabher F, Mignon F, Michel C, Rieu P, Noel N, Ryckelynck J, Lobbedez T, Dellanna F, Kleophas W, Feldkamp T, Witzke O, Nurnberger J, Zeltner R, Walz G, Zeier M, Sommerer C, Bianchi S, Capasso G, Miranda N, Magistroni R, Bracale M, Remuzzi G, Rota S, Villa G, Tilocca P, Asahi K, Kato T, Endo M, Umezono T, Fujigaki Y, Kato A, Fukatsu A, Hasegawa H, Tayama Y, Hasegawa M, Hosoya T, Hanaoka K, Iehara N, Iino Y, Tsuruoka S, Imai E, Isaka Y, Ishimura E, Ito S, Sato H, Kamata K, Sakamoto H, Kamura K, Kusano E, Muto S, Kuwahara M, Matsubara A, Yorioka N, Mochizuki T, Narita I, Naya Y, Nihei N, Yukio N, Nishio S, Nitta K, Tsuchiya K, Okamura M, Sasaki S, Rai T, Seta K, Sugawara A, Shibazaki S, Sugiyama S, Tabei K, Takaichi K, Tomita K, Kitamura K, Tsukamoto Y, Tsuruya K, Nakano T, Ubara Y, Watanabe T, Yamamoto T, Yoshida K, Ishii D, Yuzawa Y, Meijer E, Vervloet M, Ciechanowski K, Wisniewska M, Gutowska-Jablonska M, Marcinkowska-Królewicz M, Klatko W, Wiśniewski T, Klinger M, Krajewska M, Ksiazek A, Orłowska G, Malecki R, Gontarek-Kacprzak J, Nowicki M, Makówka A, Rutkowski B, Wołyniec W, Rydzewski A, Sulowicz W, Jasik P, Covic A, Volovat C, Mircescu G, Petrescu L, Bobeica R, Barbarash O, Chesnokova L, Borovoy S, Demina L, Shostka G, Idovu M, Tkalich L, Geynits O, Tomilina N, Foggensteiner L, Holt S, Kingswood J, Lambie S, Peel R, MacDougall I, Tucker B, MacPhee I, Maxwell A, Brown H, Mikhail A, Bastin L, Turner N, Neary J, Wheeler D, Maxwell P, Wilkie M, Ong A, Zehnder D, Aldridge N, Adler S, Klein M, Battle D, Bennett W, Berger B, Dell K, Blumenfeld J, Donahue S, Bolin P, Browder R, Perry A, Oskoui F, Culpepper M, Dahl N, Edelstein C, Clegg L, Fischer D, Kaplan M, Kaveh K, Pankhaniya R, Koren M, Mansur K, Lafayette R, Lamar W, Lee J, Mahnensmith R, Nachman P, Mottl A, Miskulin D, Petersen J, Radhakrishnan J, Roppolo M, Basireddy M, Rosner M, Bolton W, Schulman G, Steed L, Steinman T, Hogan M, Venuto R, Turban S, Winklhofer F., Cardiovascular Centre (CVC), Groningen Kidney Center (GKC), Torres, Ve, Chapman, Ab, Devuyst, O, Gansevoort, Rt, Grantham, Jj, Higashihara, E, Perrone, Rd, Krasa, Hb, Ouyang, J, Czerwiec, F, Tempo, Team, Gross, P, Schulze, B, Bichet, D, Chauveau, D, Peeters, P, Voiculescu, M, Manunta, P, Tuazon, J, Watnick, T, Goral, S, Horie, S, Nutahara, K, Torres, V, Chapman, A, Gansevoort, R, Perrone, R, Goldstein, S, Cowley, B, Fukagawa, M, Torra, R, Wei, Lj, Cook, T, Toto, R, Agarwal, R, August, P, Bakris, G, Beddhu, S, Corwin, H, Ruilope, L, Rosa-Diez, G, De La Fuente, J, Martin, R, Massari, P, Novoa, P, Rial, M, Wasserman, A, Faull, R, Fraser, I, Johnson, D, Pedagagos, E, Lian, M, Pollock, C, Cooper, B, Rangan, G, Russ, G, Mcdonald, S, Thomas, M, Khoo, D, Walker, R, Pirson, Y, Laecke, V, Van der Niepen, P, Sennesael, J, Barre, P, Alam, A, Soroka, S, Dieperink, H, Strandgaard, S, Petersen, L, Berthoux, F, Canaud, B, Gontiers-Picard, A, Huart, A, Combe, C, Delmas, Y, Dussol, B, Laville, M, Guebre-Egziabher, F, Mignon, F, Michel, C, Rieu, P, Noel, N, Ryckelynck, J, Lobbedez, T, Dellanna, F, Kleophas, W, Feldkamp, T, Witzke, O, Nurnberger, J, Zeltner, R, Walz, G, Zeier, M, Sommerer, C, Bianchi, S, Capasso, G, Miranda, N, Magistroni, R, Bracale, M, Remuzzi, G, Rota, S, Villa, G, Tilocca, P, Asahi, K, Kato, T, Endo, M, Umezono, T, Fujigaki, Y, Kato, A, Fukatsu, A, Hasegawa, H, Tayama, Y, Hasegawa, M, Hosoya, T, Hanaoka, K, Iehara, N, Iino, Y, Tsuruoka, S, Imai, E, Isaka, Y, Ishimura, E, Ito, S, Sato, H, Kamata, K, Sakamoto, H, Kamura, K, Kusano, E, Muto, S, Kuwahara, M, Matsubara, A, Yorioka, N, Mochizuki, T, Narita, I, Naya, Y, Nihei, N, Yukio, N, Nishio, S, Nitta, K, Tsuchiya, K, Okamura, M, Sasaki, S, Rai, T, Seta, K, Sugawara, A, Shibazaki, S, Sugiyama, S, Tabei, K, Takaichi, K, Tomita, K, Kitamura, K, Tsukamoto, Y, Tsuruya, K, Nakano, T, Ubara, Y, Watanabe, T, Yamamoto, T, Yoshida, K, Ishii, D, Yuzawa, Y, Meijer, E, Vervloet, M, Ciechanowski, K, Wisniewska, M, Gutowska-Jablonska, M, Marcinkowska-Królewicz, M, Klatko, W, Wiśniewski, T, Klinger, M, Krajewska, M, Ksiazek, A, Orłowska, G, Malecki, R, Gontarek-Kacprzak, J, Nowicki, M, Makówka, A, Rutkowski, B, Wołyniec, W, Rydzewski, A, Sulowicz, W, Jasik, P, Covic, A, Volovat, C, Mircescu, G, Petrescu, L, Bobeica, R, Barbarash, O, Chesnokova, L, Borovoy, S, Demina, L, Shostka, G, Idovu, M, Tkalich, L, Geynits, O, Tomilina, N, Foggensteiner, L, Holt, S, Kingswood, J, Lambie, S, Peel, R, Macdougall, I, Tucker, B, Macphee, I, Maxwell, A, Brown, H, Mikhail, A, Bastin, L, Turner, N, Neary, J, Wheeler, D, Maxwell, P, Wilkie, M, Ong, A, Zehnder, D, Aldridge, N, Adler, S, Klein, M, Battle, D, Bennett, W, Berger, B, Dell, K, Blumenfeld, J, Donahue, S, Bolin, P, Browder, R, Perry, A, Oskoui, F, Culpepper, M, Dahl, N, Edelstein, C, Clegg, L, Fischer, D, Kaplan, M, Kaveh, K, Pankhaniya, R, Koren, M, Mansur, K, Lafayette, R, Lamar, W, Lee, J, Mahnensmith, R, Nachman, P, Mottl, A, Miskulin, D, Petersen, J, Radhakrishnan, J, Roppolo, M, Basireddy, M, Rosner, M, Bolton, W, Schulman, G, Steed, L, Steinman, T, Hogan, M, Venuto, R, Turban, S, Winklhofer, F., University of Zurich, Torres, Vicente E, Feldkamp, Thorsten (Beitragende*r), and Witzke, Oliver (Beitragende*r)

Subjects
Male, Tolvaptan, Medizin, 2700 General Medicine, SIROLIMUS, Kidney, V2 RECEPTOR ANTAGONIST, 10052 Institute of Physiology, Aquaretic, VASOPRESSIN V-2-RECEPTOR ANTAGONIST, Polycystic Kidney, 10035 Clinic for Nephrology, Medicine (all), General Medicine, Organ Size, Middle Aged, Adolescent, Adult, Benzazepines, Double-Blind Method, Female, Glomerular Filtration Rate, Humans, Polycystic Kidney, Autosomal Dominant, Sodium, Young Adult, Antidiuretic Hormone Receptor Antagonists, LONG-ACTING SOMATOSTATIN, Autosomal Dominant, 10076 Center for Integrative Human Physiology, OPC-41061, medicine.symptom, medicine.drug, medicine.medical_specialty, RENAL-FUNCTION, CYST GROWTH, Autosomal dominant polycystic kidney disease, Urology, Renal function, Kidney Volume, 610 Medicine & health, Placebo, Article, VOLUME PROGRESSION, Cystic kidney disease, Internal medicine, medicine, HYPONATREMIA, business.industry, urogenital system, ORAL TOLVAPTAN, medicine.disease, Endocrinology, Albuminuria, 570 Life sciences, biology, business
Abstract

BACKGROUND: The course of autosomal dominant polycystic kidney disease (ADPKD) is often associated with pain, hypertension, and kidney failure. Preclinical studies indicated that vasopressin V 2 -receptor antagonists inhibit cyst growth and slow the decline of kidney function. METHODS: In this phase 3, multicenter, double-blind, placebo-controlled, 3-year trial, we randomly assigned 1445 patients, 18 to 50 years of age, who had ADPKD with a total kidney volume of 750 ml or more and an estimated creatinine clearance of 60 ml per minute or more, in a 2:1 ratio to receive tolvaptan, a V 2 -receptor antagonist, at the highest of three twice-daily dose regimens that the patient found tolerable, or placebo. The primary outcome was the annual rate of change in the total kidney volume. Sequential secondary end points included a composite of time to clinical progression (defined as worsening kidney function, kidney pain, hypertension, and albuminuria) and rate of kidney-function decline. RESULTS: Over a 3-year period, the increase in total kidney volume in the tolvaptan group was 2.8% per year (95% confidence interval [CI], 2.5 to 3.1), versus 5.5% per year in the placebo group (95% CI, 5.1 to 6.0; P

Published
2012

25. Cardiac Rhythm Disturbances in Hemodialysis Patients: Early Detection Using an Implantable Loop Recorder and Correlation With Biological and Dialysis Parameters

Author

SACHER, F., JESEL, L., BORNI-DUVAL, C., DE PRECIGOUT, V., LAVAINNE, F., BOURDENX, J. P., HADDJ-ELMRABET, A., SEIGNEURIC, B., KELLER, A., OTT, J., SAVEL, H., DELMAS, Y., BAZIN-KARA, D., KLOTZ, N., PLOUX, S., BUFFLER, S., RITTER, P., RONDEAU, Virginie, BORDACHAR, P., MARTIN, C., DEPLAGNE, A., REUTER, S., HAISSAGUERRE, M., GOURRAUD, J. B., VIGNEAU, C., MABO, P., MAURY, P., HANNEDOUCHE, T., BENARD, Antoine, and COMBE, C.

Subjects
Male, Death, Sudden, Cardiac, Renal Dialysis, Electrocardiography, Ambulatory, Humans, Arrhythmias, Cardiac, Female, Prospective Studies, Middle Aged, Aged, Electrodes, Implanted
Abstract

The aim of this study was to identify using implantable loop recorder (ILR) monitoring the mechanisms leading to sudden death (SD) in patients undergoing hemodialysis (HD).SD accounts for 11% to 25% of death in HD patients.Continuous rhythm monitoring was performed using the remote monitoring capability of the ILR device in patients undergoing HD at 8 centers. Clinical, biological, and technical HD parameters were recorded and analyzed.Seventy-one patients (mean age 65 ± 9 years, 73% men) were included. Left ventricular ejection fraction was 50% in 16%. Twelve patients (17%) had histories of atrial fibrillation or flutter at inclusion. During a mean follow-up period of 21.3 ± 6.9 months, 16 patients died (14% patient-years), 7 (44%) of cardiovascular causes. Four SDs occurred, with progressive bradycardia followed by asystole. The incidence of patients presenting with significant conduction disorder and with ventricular arrhythmia was 14% and 9% patient-years, respectively. In multivariate survival frailty analyses, a higher risk for conduction disorder was associated with plasma potassium5.0 mmol/l, bicarbonate 22 mmol/l, hemoglobin11.5 g/dl, pre-HD systolic blood pressure140 mm Hg, the longer interdialytic period, history of coronary artery disease, previous other arrhythmias, and diabetes mellitus. A higher risk for ventricular arrhythmia was associated with potassium 4.0 mmol/l, no antiarrhythmic drugs, and previous other arrhythmias. With ILR monitoring, de novo atrial fibrillation or flutter was diagnosed in 14 patients (20%).ILR may be considered in HD patients prone to significant conduction disorders, ventricular arrhythmia, or atrial fibrillation or flutter to allow early identification and initiation of adequate treatment. Therapeutic strategies reducing serum potassium variability could decrease the rate of SD in these patients. (Implantable Loop Recorder in Hemodialysis Patients [RYTHMODIAL]; NCT01252823).

Published
2017

28. Platelet transfusion and catheter insertion for plasma exchange in patients with thrombotic thrombocytopenic purpura and a low platelet count

Author

Riviere, E., SAINT-LEZER, A., James, C., Delmas, Y., CLOUZEAU, B., BUI, N., Vital, A., Coppo, P., Gruson, D., Boyer, A., Biologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases, and Université de Bordeaux (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Article RECHERCHE, equipment and supplies, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

BACKGROUND: In thrombotic thrombocytopenic purpura (TTP), platelet (PLT) transfusion is contraindicated unless a life-threatening hemorrhage occurs. However, when PLT count is low (\textless20 × 10(9) /L), their benefit-risk balance before central venous catheter (CVC) insertion for plasma exchange (PE) has not specifically been addressed in guidelines. CASE REPORTS: We report two cases in which PLTs were transfused before CVC insertion for PE, resulting in fatal myocardial infarction or neurologic complications. DISCUSSION: To date, there is a paucity of high-quality, evidence-based information on prophylactic PLT transfusion for CVC placement in TTP. Several monocenter series report that CVC could be inserted safely without PLT transfusion by experienced teams under ultrasound guidance. Uncertainty makes most physicians uncomfortable with this decision and this is a common reason why PLT transfusion remains a "precautionary" albeit misguided position. CONCLUSION: We propose a practical algorithm to avoid unnecessary PLT transfusion before CVC insertion for rapid PE in the initial management of TTP patients. We recommend no prophylactic PLT transfusion but CVC insertion in a compressible vein under ultrasound guidance by an experienced team or quick PE started on two peripheral veins if possible. PLTs should only be transfused in case of severe bleeding in association with plasma infusion and CVC insertion for immediate PE.

Published
2015

31. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies

Author

Licht, C., Greenbaum, L.A., Muus, P., Babu, S., Bedrosian, C.L., Cohen, D.J., Delmas, Y., Douglas, K., Furman, R.R., Gaber, O.A., Goodship, T., Herthelius, M., Hourmant, M., Legendre, C.M., Remuzzi, G., Sheerin, N., Trivelli, A., Loirat, C., Licht, C., Greenbaum, L.A., Muus, P., Babu, S., Bedrosian, C.L., Cohen, D.J., Delmas, Y., Douglas, K., Furman, R.R., Gaber, O.A., Goodship, T., Herthelius, M., Hourmant, M., Legendre, C.M., Remuzzi, G., Sheerin, N., Trivelli, A., and Loirat, C.

Abstract

Contains fulltext : 155154.pdf (Publisher’s version ) (Open Access), Atypical hemolytic uremic syndrome (aHUS) is a rare, possibly life-threatening disease characterized by platelet activation, hemolysis and thrombotic microangiopathy (TMA) leading to renal and other end-organ damage. We originally conducted two phase 2 studies (26 weeks and 1 year) evaluating eculizumab, a terminal complement inhibitor, in patients with progressing TMA (trial 1) and those with long duration of aHUS and chronic kidney disease (trial 2). The current analysis assessed outcomes after 2 years (median eculizumab exposure 100 and 114 weeks, respectively). At all scheduled time points, eculizumab inhibited terminal complement activity. In trial 1 with 17 patients, the platelet count was significantly improved from baseline, and hematologic normalization was achieved in 13 patients at week 26, and in 15 patients at both 1 and 2 years. The estimated glomerular filtration rate (eGFR) was significantly improved compared with baseline and year 1. In trial 2 with 20 patients, TMA event-free status was achieved by 16 patients at week 26, 17 patients at year 1, and 19 patients at year 2. Criteria for hematologic normalization were met by 18 patients at each time point. Improvement of 15 ml/min per 1.73 m(2) or more in eGFR was achieved by 1 patient at week 26, 3 patients at 1 year, and 8 patients at 2 years. The mean change in eGFR was not significant compared with baseline, week 26, or year 1. Eculizumab was well tolerated, with no new safety concerns or meningococcal infections. Thus, a 2-year analysis found that the earlier clinical benefits achieved by eculizumab treatment of aHUS were maintained at 2 years of follow-up.

Published
2015

33. Outbreak of haemolytic uraemic syndrome and bloody diarrhoea due to Escherichia coli O104:H4, south-west France, June 2011

Author

A Bone, François-Xavier Weill, Jourdan-da Silva N, P. Rolland, Christian Combe, Vendrely B, Patricia Mariani-Kurkdjian, de Valk H, Vaillant, Edouard Bingen, Desjardin M, Delmas Y, d'Andigne E, G. Gault, Muriel Macé, Charron M, L. A. King, Harold Noel, Raymond Bercion, C Castor, B. Aldabe, Nathalie Ong, Cellule interrégionale d’épidémiologie [Nouvelle Aquitaine] (CIRE), Santé publique France - French National Public Health Agency [Saint-Maurice, France], Centre National de Référence - National Reference Center Escherichia coli, Shigella et Salmonella (CNR-ESS), Institut Pasteur [Paris] (IP), AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut de Veille Sanitaire (INVS), European Centre for Disease Prevention and Control [Stockholm, Sweden] (ECDC), CHU Bordeaux [Bordeaux], Hôpital d'Instruction des Armées Robert Picqué, Service de Santé des Armées, Institut Pasteur [Paris], and European Centre for Disease Prevention and Control (ECDC)

Subjects
Adult, Diarrhea, Male, Epidemiology, Bacterial Toxins, Virulence, Microbial Sensitivity Tests, medicine.disease_cause, Polymerase Chain Reaction, Microbiology, Disease Outbreaks, Foodborne Diseases, 03 medical and health sciences, Escherichia coli O104:H4, Antibiotic resistance, Virology, Surveys and Questionnaires, Escherichia coli, Medicine, Humans, Escherichia coli Infections, ComputingMilieux_MISCELLANEOUS, 030304 developmental biology, Aged, 0303 health sciences, biology, 030306 microbiology, business.industry, Transmission (medicine), Public Health, Environmental and Occupational Health, Outbreak, Shiga toxin, Drug Resistance, Microbial, Middle Aged, 3. Good health, Immunology, Hemolytic-Uremic Syndrome, biology.protein, Female, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, France, medicine.symptom, business, Gastrointestinal Hemorrhage
Abstract

As of 12:00 28 June 2011, 15 cases of haemolytic uraemic syndrome (HUS) or bloody diarrhoea have been identified in the Gironde, south-west France. Investigations suggest the vehicle of transmission was sprouts, served at an event in Begles on 8 June 2011. A strain of shiga toxin- producing Escherichia coli O104:H4 has been isolated from five cases. This strain is genetically related to the strain identified in the recent E. coli O104:H4 outbreak in Germany, and shares the same virulence and antimicrobial resistance characteristics. .

Published
2011

34. Effet de la dialyse isonatrique par hémodiafiltration avec régénération de l’ultrafiltrat sur le contrôle tensionnel : essai randomisé contrôlé

Author

Chevalier, L., primary, Tielemans, C., additional, Debelle, F., additional, Vandervelde, D., additional, Fumeron, C., additional, Mandart, L., additional, Stolear, J.C., additional, Simon, I., additional, Delmas, Y., additional, Testa, A., additional, Tezenas, S., additional, and Mercadal, L., additional

Published
2015
Full Text
View/download PDF

36. Modelling of flexural behaviour of RC Beams subjected to localised and uniform corrosion

Author

Dekoster, M., Buyle-Bodin, François, Maurel, Olivier, Delmas, Y., Laboratoire de Mécanique de Lille - FRE 3723 (LML), Université de Lille, Sciences et Technologies-Centrale Lille-Centre National de la Recherche Scientifique (CNRS), Université de Lille, Sciences et Technologies-Ecole Centrale de Lille-Université de Lille-Centre National de la Recherche Scientifique (CNRS), and Nodot, Marie-Christine

Subjects
Finite element calculation, Flexural strength, Load-deflection curve, Rust element, Steel reinforced corosion, Ultimate deflection
Abstract

This paper presents a finite element study of corroded concrete beam flexural behaviour in which the influence of the percentage of corrosion on the load–deflection curve was studied. CASTEM 2000 computation software was used and the output compared with two experimental studies, the first on uniformly corroded beams, and the second based on a long-term experimental program inducing heterogeneously localised corrosion of beams. For the computation special elements were used to represent the interface between steel and concrete, named rust elements. A sensitivity analysis was carried out using different sizes of rust elements, in order to study their influence on analysis accuracy. The element sizes used were 1, 2, 3, 5, 10 mm. An analysis with only steel cross section reduction (PS, in French "perte de section") was also made and two concrete behaviour models were used. Comparison of the results showed good correlation between the finite element computation and the experimental studies, and highlighted the efficiency of the rust elements for the flexural behaviour study. In particular, the ultimate load and the deterioration in the stiffness with corrosion were accurately modelled. The prediction of the ultimate deflection required the use of an appropriate damage model for the concrete behaviour.

Published
2003

37. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

Author

Legendre, C.M., Licht, C., Muus, P., Greenbaum, L.A., Babu, S., Bedrosian, C., Bingham, C., Cohen, D.J., Delmas, Y., Douglas, K., Eitner, F., Feldkamp, T., Fouque, D., Furman, R.R., Gaber, O., Herthelius, M., Hourmant, M., Karpman, D., Lebranchu, Y., Mariat, C., Menne, J., Moulin, B., Nurnberger, J., Ogawa, M., Remuzzi, G., Richard, T., Sberro-Soussan, R., Severino, B., Sheerin, N.S., Trivelli, A., Zimmerhackl, L.B., Goodship, T., Loirat, C., Legendre, C.M., Licht, C., Muus, P., Greenbaum, L.A., Babu, S., Bedrosian, C., Bingham, C., Cohen, D.J., Delmas, Y., Douglas, K., Eitner, F., Feldkamp, T., Fouque, D., Furman, R.R., Gaber, O., Herthelius, M., Hourmant, M., Karpman, D., Lebranchu, Y., Mariat, C., Menne, J., Moulin, B., Nurnberger, J., Ogawa, M., Remuzzi, G., Richard, T., Sberro-Soussan, R., Severino, B., Sheerin, N.S., Trivelli, A., Zimmerhackl, L.B., Goodship, T., and Loirat, C.

Abstract

Item does not contain fulltext, BACKGROUND: Atypical hemolytic-uremic syndrome is a genetic, life-threatening, chronic disease of complement-mediated thrombotic microangiopathy. Plasma exchange or infusion may transiently maintain normal levels of hematologic measures but does not treat the underlying systemic disease. METHODS: We conducted two prospective phase 2 trials in which patients with atypical hemolytic-uremic syndrome who were 12 years of age or older received eculizumab for 26 weeks and during long-term extension phases. Patients with low platelet counts and renal damage (in trial 1) and those with renal damage but no decrease in the platelet count of more than 25% for at least 8 weeks during plasma exchange or infusion (in trial 2) were recruited. The primary end points included a change in the platelet count (in trial 1) and thrombotic microangiopathy event-free status (no decrease in the platelet count of >25%, no plasma exchange or infusion, and no initiation of dialysis) (in trial 2). RESULTS: A total of 37 patients (17 in trial 1 and 20 in trial 2) received eculizumab for a median of 64 and 62 weeks, respectively. Eculizumab resulted in increases in the platelet count; in trial 1, the mean increase in the count from baseline to week 26 was 73x10(9) per liter (P<0.001). In trial 2, 80% of the patients had thrombotic microangiopathy event-free status. Eculizumab was associated with significant improvement in all secondary end points, with continuous, time-dependent increases in the estimated glomerular filtration rate (GFR). In trial 1, dialysis was discontinued in 4 of 5 patients. Earlier intervention with eculizumab was associated with significantly greater improvement in the estimated GFR. Eculizumab was also associated with improvement in health-related quality of life. No cumulative toxicity of therapy or serious infection-related adverse events, including meningococcal infections, were observed through the extension period. CONCLUSIONS: Eculizumab inhibited complement-mediated

Published
2013

39. Determinants of arterial compliance in patients treated by hemodialysis

Author

Level, C., Lasseur, C., Delmas, Y., Cazin, M. C., Vendrely, B., Chauveau, P., Gosse, P., and Christian Combe

Subjects
Adult, Aged, 80 and over, Peripheral Vascular Diseases, Arteries, Middle Aged, Echocardiography, Renal Dialysis, Risk Factors, Hypertension, Electrocardiography, Ambulatory, Humans, Kidney Failure, Chronic, Calcium, Aged, Compliance
Abstract

Cardiovascular disease is the principal cause of morbidity and mortality among hemodialysis patients. Several studies have demonstrated the importance of a reduction in arterial compliance in the development of cardiovascular complications, reflecting the interaction of functional and structural alterations of the peripheral arterial system and left ventricle. The aim of the present study was to demonstrate that arterial compliance, evaluated by automated recording of the QKd interval, was lower in hemodialysis patients than in normal subjects. A secondary objective of the study was to assess the influence of several factors, including calcium-phosphorus parameters, on decreased arterial compliance in these patients.Arterial compliance was evaluated in 24 chronic hemodialysis patients who had normal (n = 12) or high blood pressure (n = 12), using a method of measuring systolic wave velocity by automated recording of the QKd interval. This interval corresponds to the time (in ms) between the onset of the electrocardiogram QRS complex (Q) and the Korotkoff (K) sound at diastolic pressure (d) heard over the brachial artery during blood pressure measurement. The analysis was performed in comparison with reference values obtained in a population with normal renal function. The other parameters determined were: age, duration of chronic renal failure, duration of hemodialysis therapy, left ventricular mass, vascular calcification score, serum total and ionized calcium, phosphorus, parathyroid hormone, calcidiol, calcitriol, and blood concentration of hemoglobin.The arterial stiffness of all the patients was increased significantly (p0.001) compared to reference values obtained from subjects without renal failure, the average age, height, and blood pressure of whom were similar to those of the patients. Multivariate analysis demonstrated a positive relationship among the QKd interval, serum total calcium, and the duration of hemodialysis. This suggested that arterial wall elastic properties were dependent not only on hypertension and constraints of pressure, but that they were also influenced by calcium and phosphorus metabolism and the duration of renal substitution therapy.Arterial compliance, evaluated by the ambulatory method of QKd measurement, is reduced in chronic hemodialysis patients, and is inversely correlated with serum calcium concentration and dependent on the previous duration of hemodialysis therapy.

Published
2002

40. Genetic diseases and molecular genetics

Author

Legendre, C., primary, Cohen, D., additional, Delmas, Y., additional, Feldkamp, T., additional, Fouque, D., additional, Furman, R., additional, Gaber, O., additional, Greenbaum, L., additional, Goodship, T., additional, Haller, H., additional, Herthelius, M., additional, Hourmant, M., additional, Licht, C., additional, Moulin, B., additional, Sheerin, N., additional, Trivelli, A., additional, Bedrosian, C. L., additional, Loirat, C., additional, Legendre, C., additional, Babu, S., additional, Jungraithmayr, T., additional, Lebranchu, Y., additional, Riedl, M., additional, Gaber, A. O., additional, Bedrosian, C., additional, Muus, P., additional, Douglas, K., additional, Remuzzi, G., additional, Kourouklaris, A., additional, Ioannou, K., additional, Athanasiou, I., additional, Demetriou, K., additional, Panagidou, A., additional, Zavros, M., additional, Rodriguez C, N. Y., additional, Blasco, M., additional, Arcal, C., additional, Quintana, L. F., additional, Rodriguez de Cordoba, S., additional, Campistol, J. M., additional, Bachmann, N., additional, Eisenberger, T., additional, Decker, C., additional, Bolz, H. J., additional, Bergmann, C., additional, Pesce, F., additional, Cox, S. N., additional, Serino, G., additional, De Palma, G., additional, Sallustio, F. P., additional, Schena, F., additional, Falchi, M., additional, Pieri, M., additional, Stefanou, C., additional, Zaravinos, A., additional, Erguler, K., additional, Lapathitis, G., additional, Dweep, H., additional, Sticht, C., additional, Anastasiadou, N., additional, Zouvani, I., additional, Voskarides, K., additional, Gretz, N., additional, Deltas, C. C., additional, Ruiz, A., additional, Bonny, O., additional, Sallustio, F., additional, Curci, C., additional, Cox, S., additional, Kemter, E., additional, Sklenak, S., additional, Aigner, B., additional, Wanke, R., additional, Kitzler, T. M., additional, Moskowitz, J. L., additional, Piret, S. E., additional, Lhotta, K., additional, Tashman, A., additional, Velez, E., additional, Thakker, R. V., additional, Kotanko, P., additional, Leierer, J., additional, Rudnicki, M., additional, Perco, P., additional, Koppelstaetter, C., additional, Mayer, G., additional, Sa, M. J. N., additional, Alves, S., additional, Storey, H., additional, Flinter, F., additional, Willems, P. J., additional, Carvalho, F., additional, Oliveira, J., additional, Arsali, M., additional, Papazachariou, L., additional, Demosthenous, P., additional, Lazarou, A., additional, Hadjigavriel, M., additional, Stavrou, C., additional, Yioukkas, L., additional, Deltas, C., additional, Pierides, A., additional, Kkolou, M., additional, Toka, H. R., additional, Dibartolo, S., additional, Lanske, B., additional, Brown, E. M., additional, Pollak, M. R., additional, Familiari, A., additional, Zavan, B., additional, Sanna Cherchi, S., additional, Fabris, A., additional, Cristofaro, R., additional, Gambaro, G., additional, D'Angelo, A., additional, Anglani, F., additional, Toka, H., additional, Mount, D., additional, Pollak, M., additional, Curhan, G., additional, Sengoge, G., additional, Bajari, T., additional, Kupczok, A., additional, von Haeseler, A., additional, Schuster, M., additional, Pfaller, W., additional, Jennings, P., additional, Weltermann, A., additional, Blake, S., additional, Sunder-Plassmann, G., additional, Kerti, A., additional, Csohany, R., additional, Wagner, L., additional, Javorszky, E., additional, Maka, E., additional, Tulassay, T., additional, Tory, K., additional, Kingswood, J., additional, Nikolskaya, N., additional, Mbundi, J., additional, Jozwiak, S., additional, Belousova, E., additional, Frost, M., additional, Kuperman, R., additional, Bebin, M., additional, Korf, B., additional, Flamini, R., additional, Kohrman, M., additional, Sparagana, S., additional, Wu, J., additional, Brechenmacher, T., additional, Stein, K., additional, Bissler, J., additional, Franz, D., additional, Zonnenberg, B., additional, Cheung, W., additional, Wang, J., additional, Lam, D., additional, Budde, K., additional, Ivanitskiy, L., additional, Sowershaewa, E., additional, Krasnova, T., additional, Samokhodskaya, L., additional, Safarikova, M., additional, Jana, R., additional, Jitka, S., additional, Obeidova, L., additional, Kohoutova, M., additional, Tesar, V., additional, Evrengul, H., additional, Ertan, P., additional, Serdaroglu, E., additional, Yuksel, S., additional, Mir, S., additional, Yang n Ergon, E., additional, Berdeli, A., additional, Zawada, A., additional, Rogacev, K., additional, Rotter, B., additional, Winter, P., additional, Fliser, D., additional, Heine, G., additional, Bataille, S., additional, Moal, V., additional, Berland, Y., additional, Daniel, L., additional, Rosado, C., additional, Bueno, E., additional, Fraile, P., additional, Lucas, C., additional, Garcoa-Cosmes, P., additional, Tabernero, J. M., additional, Gonzalez, R., additional, Garcia-Cosmes, P., additional, Silska-Dittmar, M., additional, Zaorska, K., additional, Malke, A., additional, Musielak, A., additional, Ostalska-Nowicka, D., additional, Zachwieja, J., additional, K d r, V., additional, Uz, E., additional, Yigit, A., additional, Altuntas, A., additional, Yigit, B., additional, Inal, S., additional, Sezer, M., additional, Yilmaz, R., additional, Visciano, B., additional, Porto, C., additional, Acampora, E., additional, Russo, R., additional, Riccio, E., additional, Capuano, I., additional, Parenti, G., additional, Pisani, A., additional, Feriozzi, S., additional, Perrin, A., additional, West, M., additional, Nicholls, K., additional, Torras, J., additional, Cybulla, M., additional, Conti, M., additional, Angioi, A., additional, Floris, M., additional, Melis, P., additional, Asunis, A. M., additional, Piras, D., additional, Pani, A., additional, Warnock, D., additional, Guasch, A., additional, Thomas, C., additional, Wanner, C., additional, Campbell, R., additional, Vujkovac, B., additional, Okur, I., additional, Biberoglu, G., additional, Ezgu, F., additional, Tumer, L., additional, Hasanoglu, A., additional, Bicik, Z., additional, Akin, Y., additional, Mumcuoglu, M., additional, Ecder, T., additional, Paliouras, C., additional, Mattas, G., additional, Papagiannis, N., additional, Ntetskas, G., additional, Lamprianou, F., additional, Karvouniaris, N., additional, and Alivanis, P., additional

Published
2013
Full Text
View/download PDF

42. Outbreak of Shiga Toxin-Producing Escherichia coli O104:H4 Associated With Organic Fenugreek Sprouts, France, June 2011

Author

King, L. A., primary, Nogareda, F., additional, Weill, F.-X., additional, Mariani-Kurkdjian, P., additional, Loukiadis, E., additional, Gault, G., additional, Jourdan-DaSilva, N., additional, Bingen, E., additional, Mace, M., additional, Thevenot, D., additional, Ong, N., additional, Castor, C., additional, Noel, H., additional, Van Cauteren, D., additional, Charron, M., additional, Vaillant, V., additional, Aldabe, B., additional, Goulet, V., additional, Delmas, G., additional, Couturier, E., additional, Le Strat, Y., additional, Combe, C., additional, Delmas, Y., additional, Terrier, F., additional, Vendrely, B., additional, Rolland, P., additional, and de Valk, H., additional

Published
2012
Full Text
View/download PDF

48. Household transmission of haemolytic uraemic syndrome associated with Escherichia coli O104:H4, south-western France, June 2011

Author

Aldabe, B, primary, Delmas, Y, additional, Gault, G, additional, Vendrely, B, additional, Llanas, B, additional, Charron, M, additional, Castor, C, additional, Ong, N, additional, Weill, F X, additional, Mariani-Kurkdjian, P, additional, Terrier, F, additional, Desjardin, M, additional, Simões, J, additional, Le Bihan, B, additional, Combe, C, additional, and Rolland, P, additional

Published
2011
Full Text
View/download PDF

49. Outbreak of haemolytic uraemic syndrome and bloody diarrhoea due to Escherichia coli O104:H4, south-west France, June 2011

Author

Gault, G, primary, Weill, F X, additional, Mariani-Kurkdjian, P, additional, Jourdan-da Silva, N, additional, King, L, additional, Aldabe, B, additional, Charron, M, additional, Ong, N, additional, Castor, C, additional, Macé, M, additional, Bingen, E, additional, Noël, H, additional, Vaillant, V, additional, Bone, A, additional, Vendrely, B, additional, Delmas, Y, additional, Combe, C, additional, Bercion, R, additional, d'Andigné, E, additional, Desjardin, M, additional, Rolland, P, additional, and de Valk, H, additional

Published
2011
Full Text
View/download PDF

50. Pathophysiology and clinical studies in CKD 1-5.

Author

El Sharkawy, M., primary, Elsaeed, K., additional, Kamel, M., additional, Aziz, A., additional, Del Pozo, C., additional, Balk, A., additional, Castello-Banyuls, J., additional, Navarro, D., additional, Pere, B., additional, Faura, C. C., additional, Ballesta, J. J., additional, Rodig, N., additional, Vilalta, R., additional, Hernandez, J., additional, Camacho Diaz, J., additional, Lapeyraque, A.- L., additional, Sherwinter, J., additional, Gruppo, R., additional, Fremont, O., additional, Baudouin, V., additional, Langman, C., additional, Simonetti, G. D., additional, Loirat, C., additional, Muus, P., additional, Legendre, C., additional, Douglas, K., additional, Hourmant, M., additional, Delmas, Y., additional, Herthelius, M., additional, Trivelli, A., additional, Goodship, T., additional, Bedrosian, C., additional, Licht, C., additional, Schlesinger, N., additional, Lin, H.- Y., additional, De Meulemeester, M., additional, Rovensky, J., additional, Krammer, G., additional, Balfour, A., additional, So, A., additional, Carrero, J. J., additional, Sonmez, A., additional, Saglam, M., additional, Stenvinkel, P., additional, Yaman, H., additional, Quresi, A. R., additional, Yenicesu, M., additional, Yilmaz, M. I., additional, McQuarrie, E., additional, Freel, M., additional, Mark, P., additional, Patel, R., additional, Steedman, T., additional, Fraser, R., additional, Dargie, H., additional, Connell, J., additional, Jardine, A., additional, Oh, S. W., additional, Chin, H. J., additional, Na, K. Y., additional, Chae, D. W., additional, Alfieri, C., additional, Vettoretti, S., additional, Cafforio, C., additional, Floreani, R., additional, Bonanomi, C., additional, Danzi, G., additional, Messa, P., additional, Whelton, A., additional, MacDonald, P., additional, Hunt, B., additional, Gunawardhana, L., additional, Rusu, E., additional, Voiculescu, M., additional, Zilisteanu, D., additional, Ecobici, M., additional, Arsenescu, I., additional, Ismail, G., additional, Macarie, C., additional, Chan, D., additional, Irish, A., additional, Watts, G., additional, Dogra, G., additional, Krueger, T., additional, Schlieper, G., additional, Cozzolino, M., additional, Eckardt, K. U., additional, Jadoul, M., additional, Ketteler, M., additional, Leunissen, K., additional, Rump, L. C., additional, Wiecek, A., additional, Westenfeld, R., additional, Hilgers, R. D., additional, Mahnken, A. H., additional, Schurgers, L. J., additional, Floege, J., additional, Onuigbo, M., additional, Onuigbo, N., additional, Trevisani, F., additional, Sciarrone Alibrandi, M. T., additional, Bertini, R., additional, Montorsi, F., additional, Delli Carpini, S., additional, Camerota, T. C., additional, Antoniolli, S., additional, Citterio, L., additional, Querques, M., additional, Merlino, L., additional, Manunta, P., additional, Ebah, L., additional, Morgan, J., additional, Brenchley, P., additional, Mitra, S., additional, Krumme, B., additional, Boehler, J., additional, Mettang, T., additional, Strutz, F., additional, Georginova, O., additional, Rykova, S., additional, Gafarova, M., additional, Smyr, K., additional, Sokolova, I., additional, Krasnova, T., additional, and Kozlovskaya, L., additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results